<DOC>
	<DOCNO>NCT00942968</DOCNO>
	<brief_summary>The purpose study determine long term tolerability safety dalteparin subject cancer .</brief_summary>
	<brief_title>Evaluation Dalteparin Long-term ( One Year ) Treatment Blood Clots Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Male female subject , age great equal 18 year age . 2 . Females either nonchildbearing potential result surgery , radiation therapy , menopause ( one year post onset ) , childbearing potential willing adhere acceptable method pregnancy prevention . 3 . Subjects must newly diagnose , symptomatic proximal deepvein thrombosis low extremity , pulmonary embolism , . 4 . Subjects must active malignancy define diagnosis cancer ( exclude basal cell squamous cell carcinoma skin ) within six month enrollment , receive treatment cancer within previous six month , document recurrent metastatic cancer . 5 . Prior enrollment , subject must receive therapeutic dos anticoagulant therapy ( include low molecular weight heparin [ LMWH ] ) &gt; 48 hour ( &gt; 4 dos within 48 hour ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 7 . Subjects must life expectancy &gt; 6 month . 8 . Subjects must platelet count &gt; 75,000 mm^3 . 9 . The subject must oral anticoagulant therapy concomitant disease . 10 . Subjects must active serious bleed episode within two week prior study entry . 11 . Subjects must able comply schedule followup . 1 . Subjects high risk serious bleeding ( e.g. , recent neurosurgery within 30 day , history intracranial hemorrhage , acute gastroduodenal ulcer , etc. ) . 2 . Subjects hemodialysis . 3 . Subjects prior placement Greenfield filter device prevent embolization deep vein thromboses . 4 . Subjects know contraindication use heparin ( e.g. , heparininduced thrombocytopenia ) . 5 . Subjects know hypersensitivity heparin , dalteparin sodium , LMWHs pork product . 6 . Subjects currently participate another clinical trial involve anticoagulation therapy ( exception acetylsalicylic acid ( ASA ) 30 day prior study entry , actively use investigational drugs/treatments 30 day prior study entry involve anticoagulation therapy ( exception ASA , t.i.d ) . 7 . Subject pregnant breast feeding . 8 . Subjects uncontrolled hypertension characterize sustain systolic pressure &gt; 170 mmHg and/or diastolic pressure &gt; 100 mmHg . 9 . Subjects serious concomitant systemic disorder ( example , active infection include HIV cardiac disease ) opinion investigator , would compromise subject 's ability complete study . 10 . Any condition make subject unsuitable opinion investigator . 11 . Subjects leukemia myeloproliferative syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>